Bacterial Infections in Patients with Cancer: New Challenges, New Opportunities Post Test and Evaluation Please note that to receive credit you must achieve a score of at least 70%. Physicians: Certificate of Credit will be emailed within 4 weeks of successful completion of the activity. Pharmacists: The information that you participated will be uploaded to CPE Monitor within 4 weeks of successful completion of the activity and you will be able to access your credits from the profile you set up with NABP. For more information, please visit http://www.nabp.net/. Question Title 1. Risk factors for the development of C. difficile infection (CDI) include all of the following except: Acquisition of a non-NAP1 strain Chemotherapy Advanced age Immunosuppression Question Title 2. The least sensitive method to diagnose CDI is: Tissue culture cytotoxicity Nucleic acid amplification tests (NAAT) Toxin enzyme immunoassay (EIA) Stool culture Question Title 3. The recommended antimicrobial treatment for severe CDI (i.e., WBC ≥15,000 cells/mcL) is: Metronidazole Vancomycin Metronidazole plus vancomycin Rifaximin Question Title 4. The recurrence rate after a first episode of CDI is approximately: 10% 20% 40% 60% Question Title 5. The most common site of bacterial infection in cancer patients is: Bloodstream Respiratory tract Gastrointestinal tract Skin and skin structure Question Title 6. The most common etiology of Gram-positive bacterial infections in cancer patients is: Staphylococcus aureus Viridans group streptococci Coagulase-negative staphylococci Enterococcus species Question Title 7. Which of the following antimicrobials exhibits activity primarily against Gram-negative bacteria? Ceftolozane Daptomycin Linezolid Oritavancin Question Title 8. Approximately what percent of patients with hematologic malignancies develop bacteremia during febrile neutropenic episodes? Up to 5% Up to 10% Up to 25% Up to 50% Question Title 9. Recommended initial treatment of infection caused by ESBL-producing bacteria is a(n): Fluoroquinolone Fourth-generation cephalosporin Aminoglycoside Carbapenem Question Title 10. Empiric antimicrobial therapy for a high-risk hematologic patient with fever and neutropenia should include a(n): Anti-pseudomonal beta-lactam Aminoglycoside Fluoroquinolone Macrolide Next